Financhill
Back

Spero Therapeutics Quote, Financials, Valuation and Earnings

Spero Therapeutics Price Quote

$1.18
+0.02 (+-0.84%)
(Updated: November 23, 2024 at 5:55 AM ET)

Spero Therapeutics Key Stats

Sell
15
Spero Therapeutics (SPRO) is a Sell

Day range:
$1.14 - $1.23
52-week range:
$1.01 - $1.89
Dividend yield:
0%
P/E ratio:
2.70
P/S ratio:
0.70
P/B ratio:
0.97%

Volume:
391.1K
Avg. volume:
353.9K
1-year change:
-4.13%
Market cap:
$63.2M
Revenue:
$96.7M
EPS:
$0.08

How Much Does Spero Therapeutics Make?

Is Spero Therapeutics Growing As A Company?

  • What Is Spero Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.67%
  • What Is Spero Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Spero Therapeutics Stock Price Performance

What Is Spero Therapeutics 52-Week High & Low?

Spero Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Spero Therapeutics?

Is Spero Therapeutics Cash Flow Positive?

  • What Is SPRO Cash Flow From Operations?
    Cash flow from operations (TTM) is -$17.5M
  • What Is Spero Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $0
  • What Is Spero Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $0

Spero Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    SPRO return on invested capital is 4.36%
  • What Is Spero Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is 2.37%
  • What Is SPRO Return On Equity?
    ROE is a measure of profitability and is 4.36%

Spero Therapeutics Earnings Date & Stock Price

Spero Therapeutics Competitors

  • Who Are Spero Therapeutics's Competitors?
    Below is a list of companies who compete with Spero Therapeutics or are related in some way:
    • Arbutus Biopharma Corp (ABUS)
    • CytomX Therapeutics Inc (CTMX)
    • Equillium Inc (EQ)
    • Johnson & Johnson (JNJ)
    • NovaBay Pharmaceuticals Inc (NBY)

Spero Therapeutics Dividend Yield

Spero Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 11.93%
Revenue: -66.56% 75.68%

Analyst Recommendations

Buy Recommendations: 2
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 5.00
Upside from Last Price: 331.03%

Major Shareholders

  • How many SPRO shares are owned by institutional investors?
    18.4M SPRO shares are owned by institutional investors
  • How many SPRO shares are owned by insiders?
    4.7M SPRO shares are owned by insiders